Premier épisode de rejet aigu après transplantation rénale : étude des caractéristiques histopathologiques en fonction du risque immunologique du patient

Wolfe, 1999, Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant, N Engl J Med, 341, 1725, 10.1056/NEJM199912023412303 Danovitch, 2005 Pallardo Mateu, 2004, Acute rejection and late renal transplant failure: risk factors and prognosis, Nephrol Dial Transplant, 19, iii38, 10.1093/ndt/gfh1013 Mange, 2003, Dialysis prior to living donor kidney transplantation and rates of acute rejection, Nephrol Dial Transplant, 18, 172, 10.1093/ndt/18.1.172 Wissing KM, Fomegné G, Broeders N, Ghisdal L, Abramowicz D. HLA B and DR, mismatches remain significant risk factors for acute rejection of kidney allografts in patients receiving anti-IL2 receptor antibodies, calcineurin inhibitors and mycophenolate mofetil. [abstract]. Congrès annuel de la Société américaine de transplantation. 2006. Dragun, 2005, Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection, N Engl J Med, 352, 558, 10.1056/NEJMoa035717 Bohmig, 2001, C4d-positive acute humoral renal allograft rejection: effective treatment by immunoadsorption, J Am Soc Nephrol, 12, 2482, 10.1681/ASN.V12112482 Mauiyyedi, 2002, Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification, J Am Soc Nephrol, 13, 779, 10.1681/ASN.V133779 Racusen, 1999, The Banff 97 working classification of renal allograft pathology, Kidney Int, 55, 713, 10.1046/j.1523-1755.1999.00299.x Racusen, 2003, Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection, Am J Transplant, 3, 708, 10.1034/j.1600-6143.2003.00072.x Crespo, 2001, Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics, Transplantation, 71, 652, 10.1097/00007890-200103150-00013 Halloran, 1992, The significance of the anti-class I response. II. Clinical and pathologic features of renal transplants with anti-class I-like antibody, Transplantation, 53, 550, 10.1097/00007890-199203000-00011 Trpkov, 1996, Pathologic features of acute renal allograft rejection associated with donor-specific antibody, Analysis using the Banff grading schema, Transplantation, 61, 1586, 10.1097/00007890-199606150-00007 Regele, 2001, Endothelial C4d deposition is associated with inferior kidney allograft outcome independently of cellular rejection, Nephrol Dial Transplant, 16, 2058, 10.1093/ndt/16.10.2058 Nickeleit, 2002, Detection of the complement degradation product C4d in renal allografts: diagnostic and therapeutic implications, J Am Soc Nephrol, 13, 242, 10.1681/ASN.V131242 Hardy, 2001, Sensitization 2001, Clin Transpl, 271–8, 271 Mourad, 2004, Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids, Transplantation, 78, 584, 10.1097/01.TP.0000129812.68794.CC Cai, 2005, Humoral theory of transplantation: mechanism, prevention, and treatment, Hum Immunol, 66, 334, 10.1016/j.humimm.2005.01.021 Nadasdy, 2005, Comparative study for the detection of peritubular capillary C4d deposition in human renal allografts using different methodologies, Hum Pathol, 36, 1178, 10.1016/j.humpath.2005.08.002 Feucht, 2003, Complement C4d in graft capillaries -- the missing link in the recognition of humoral alloreactivity, Am J Transplant, 3, 646, 10.1034/j.1600-6143.2003.00171.x Mizutani, 2005, Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure, Am J Transplant, 5, 2265, 10.1111/j.1600-6143.2005.01016.x